Categories
Product

Unlocking Real-World Insights into IBD Treatment: The Power of Clinical EHR and Physician Notes Integration

At OMNY Health, we believe that unlocking the full potential of healthcare data means going beyond structured fields in Electronic Health Records (EHRs). By combining EHR data with unstructured clinical notes, we can uncover insights that truly reflect the complexities of patient care—insights that are often hidden in claims or EHR data alone.

Our recent study on Inflammatory Bowel Disease (IBD) treatment patterns highlights the unique value of integrating EHR data with clinical notes. Using Large Language Models (LLMs), we analyzed over 10.6 million clinical notes from our health systems to explore why IBD patients switch or discontinue biologic treatments. This approach gave us a comprehensive, real-world view of treatment decisions. We identified 7 distinct reasons for treatment alteration across 7 biologics.

Key Findings: Uncovering the Real Reasons for Treatment Changes

While traditional EHRs track structured data like medication prescriptions and diagnoses, they often miss the “why” behind treatment decisions. Our study revealed seven key reasons why biologic treatments are altered, based on unstructured notes that provide deeper context:

  • Adverse Drug Events (16-28%)
  • Finance-Related Reasons (4-24%)
  • Patient-Related Factors (2-9%)
  • Lack of Efficacy (1-14%)
  • Symptom Resolution (1-4%)
  • Drug-Disease Interactions (1-3%)
  • Obstetric Concerns (0-2%)

Figure 1. Reasons for Biologic Switching in IBD

BiologicAdverse Drug Event (%)Drug-Disease Interaction (%)Symptom Resolution (%)Finance Related (%)Patient Related (%)Not Effective (%)Obstetric (%)
Infliximab28.261.922.8724.428.6214.370.48
Adalimumab26.822.871.4412.938.142.871.92
Golimumab0.9600.481.440.4800
Certolizumab1.92000.96000
Vedolizumab16.280.964.317.186.701.441.92
Ustekinumab11.010.4803.832.3900
Risankizumab0.960000.4800

Transforming IBD Care: From Data to Insight

By analyzing clinical notes, OMNY Health’s AI models identified reasons for treatment alterations with 94.5% accuracy. This level of insight isn’t typically captured in structured EHR fields, and it has significant implications for improving patient care.

Understanding the real-world reasons behind treatment changes is essential for refining treatment strategies, improving adherence, and ultimately achieving better patient outcomes. For IBD patients, this means more personalized care tailored to their unique circumstances—whether that’s a financial hurdle, an adverse drug reaction, or a need for a more effective therapy.

The Future of Healthcare Data: A New Era of Personalized Care

At OMNY Health, we’re excited about the future of healthcare data. By integrating EHRs with unstructured clinical notes and leveraging the power of AI, we can identify patterns that were previously overlooked. This approach not only improves our understanding of IBD treatment but also has the potential to transform how we approach care across a wide range of conditions.

Categories
News

OMNY Health Launches Data Platform Designed to Power AI-Driven Health Tech Companies

OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data sharing launched its platform designed to power AI-driven health technology companies, further cementing the company’s commitment to democratizing healthcare data. QuantHealth and ArisGlobal are just two of OMNY’s newest partners to leverage this new platform to power their organizational AI-driven needs. OMNY Health’s data network uniquely addresses Generative AI’s need for large de-identified structured and unstructured electronic health record (EHR) data sets across diverse provider and patient populations, further underscoring the platform as delivering the data infrastructure and rails for provider organizations to collaborate and fuel the development and use of effective AI solutions for advancing healthcare.

“Our mission is to free data from silos, allowing it to be shared, analyzed, and morphed into life-saving treatments and better care for patients,” said Mitesh Rao, CEO, OMNY Health. “Life science organizations and providers often struggle with time and budget constraints that hinder their ability to learn from their data. Our work powering AI-driven platforms can unblock this process by partnering with AI developers with data and tools to accelerate breakthrough therapies and monitor new therapies for safety signals to ensure patient populations remain safe.”

Two of OMNY Health’s AI-driven partners being effectively powered by the platform’s data to foster new opportunities for advancing healthcare include QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®.

QuantHealth’s AI technology, trained on a dataset of 350 million patients, enhances clinical trial timelines, mitigates trial risks, and identifies populations likely to respond to treatments. OMNY’s collaboration will help QuantHealth’s pharmaceutical partners expedite drug development through simulated clinical trials, utilizing real-world evidence to predict clinical trial outcomes, drug efficacy, and patient responses.

“Biotech is entering a vibrant part of life sciences history,” said Omri Matalon, VP Clinical Data Science and Head of R&D Operations at QuantHealth. “This partnership furthers our commitment to quality data and access for our life sciences partners. By integrating diverse EHRs into organized, de-identified research data products, we can address disparities in clinical trials and close significant demographic information gaps in drug discovery and development.”

OMNY’s partnership with ArisGlobal, a leader in pharmacovigilance, safety monitoring, and reporting systems, will transform safety signal validation and pave the way for comprehensive, proactive signal detection.

“Up to 95% of adverse event cases go unreported today, while processing ICSRs can be time consuming, and analysis of medical literature and online forums is slow and inefficient,” said Ann-Marie Orange, CIO and Global Head of R&D at ArisGlobal. “Combining LifeSphere products with comprehensive real-time RWD addresses these challenges head-on. By leveraging advanced technology and insights from extensive RWD, we are reshaping drug discovery and development.”

These partnerships demonstrate OMNY Health’s commitment to AI-enabled healthcare improvement through acceleration of diverse participation in clinical trials and the support of research programs that aim to save lives and improve patient outcomes. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit https://marketing-dev.omnyhealth.com/.

About OMNY Health

OMNY Health™ is a national data ecosystem connecting the world of healthcare to fuel partnerships that improve clinical outcomes and drive patient care. OMNY’s dynamic partnerships with specialty health networks, healthcare systems, academic medical centers, and integrated delivery networks span all fifty states and cover over 75 million patient lives. The company’s comprehensive data layer powers health tech companies to drive the next generation of innovation. The platform serves as a centralized resource for life sciences and healthcare provider groups to facilitate mutually-beneficial data sharing and research collaboration at scale, fueling innovation where patients need it the most. OMNY Health’s data ecosystem now reflects more than seven years of historical data encompassing more than 2 billion clinical notes from 300,000+ providers across 200+ specialties – and is growing. For more information, visit www.marketing-dev.omnyhealth.com.

About ArisGlobal

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn or visit https://www.arisglobal.com/.

About QuantHealth

90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth’s Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly. Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth’s simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai/.

Categories
News Product

Five Natural Language Processing Subtasks that Large Language Models Can Perform to Improve Healthcare

In late 2022, the technology world was turned upside down as OpenAI released ChatGPT, its new artificial intelligence (AI) model.  Unlike most previous natural language processing (NLP) models, this model contained billions of parameters, was trained on a corpus of unstructured data with unprecedented size, and underwent a novel alignment process to better orient the model towards human needs.  The result was a model that provided superior performance for various NLP-related tasks and professional certification exams (including medical ones) and could produce realistic-sounding text that even the most hardened AI cynics could not deny.  Technological and legal impacts were felt almost immediately. Many technology companies began to invest in the new field of generative artificial intelligence (genAI) with an eye toward the potential for financial benefits. 

However, lost in all the excitement, is the fact that genAI relies largely on the bread-and-butter NLP methods and subtasks that have supported and improved many industries, including healthcare, over the past decade or two, with the additional capability of text generation.  Unlike previous NLP models, newer large language models (LLMs) can perform many different NLP subtasks with one single model. 

So, what are the different subtasks that a state-of-the-art LLM can perform? Without further ado, here are five NLP subtasks that can be programmed into LLM to improve healthcare:

Text Classification

Text classification, or the task of distributing text into categories, is often seen as the most primitive NLP subtask.  A classic non-healthcare example of this subtask is categorizing reviews (e.g., critiquing products or movies) into having positive or negative sentiments. Text can be classified at the sentence or paragraph level, depending on the use case.   

In healthcare, the clinical notes for patients can be classified as to whether they identify patients as having certain attributes or disease characteristics.  Using that information, appropriate personalized interventions and treatments can then be used to improve health.  Over the past year, work at OMNY Health has focused on several text classification projects, including the following:

  1. Classifying generalized pustular psoriasis (GPP) patients or patients with a rare, devastating form of the skin disease psoriasis, by their disease status (flare versus non-flare) in collaboration with a life sciences partner. 
  2. Classifying psoriasis patients as to whether they received joint assessments and/or rheumatology referrals in the presence of psoriatic arthritis symptoms, in collaboration with life sciences partners. 
  3. Identifying patients adversely affected by social determinants of health, including illiteracy and financial and housing insecurity. 

The results of the study are available (View Report).

Named Entity Recognition

Also known as token classification, named entity recognition (NER) involves classifying individual words or phrases as reflective of an entity, for example, a person, place, or organization.  It differs from text classification in that every word is classified, unlike text classification in which sentences and paragraphs are classified.

In healthcare, common entities detected include symptoms, medications, and protected health information (PHI). PHI may be related to individuals, such as names, addresses, and contact information, in larger efforts to deidentify clinical notes before their input in an NLP model.  In fact, at OMNY Health, more than 20 PHI entities are identified and removed from clinical text before NLP to protect patient privacy and to comply with the Health Insurance Portability and Accountability Act (HIPAA) of 1996.

Relation Extraction

Relation extraction (RE) represents a relatively more complex subtask in which the relationships between various entities are determined.  For example, if two “person” entities are detected in the text, an RE task may be used to identify whether the two entities are married.  It is usually performed downstream of an NER step.  Previously, RE tasks often required expensive annotation and labeling processes to be performed successfully, although this requirement has faded with the advent of newer LLMs that can label and annotate notes automatically.

In healthcare, RE applications include identifying patient-doctor relationships for clinical note understanding, as well as more general clinical RE to model medical knowledge ontologies such as the Systematic Nomenclature in Medicine – Clinical Terms (SNOMED-CT).  At OMNY Health, work has been performed to identify relations between detected symptom and medication entity-pairs to determine if they comprised an adverse drug event (ADE).

Closed-domain Question Answering

Closed-domain question answering is an NLP subtask in which a text is paired with a question about the text, like a reading comprehension question on a standardized exam.  The question-context pair is then passed to an NLP model, which then extracts the answer to the question from the text.

In healthcare, question-answering pipelines can be performed to extract practically any conceivable information about a patient from clinical notes, when paired with the correct prompt.  The answer can then be processed and refined using additional NLP steps.  As an example, a clinical note about medication discontinuation could be passed as input to an NLP model paired with the question, “Why was the medication discontinued?”  The answer could then be passed to a text classification model which categorizes the reason for treatment discontinuation.  At OMNY Health, we have constructed such a pipeline to determine reasons for treatment discontinuation for various medications (View Report).  A second application of question-answering is the extraction of severity scores from clinical notes for various diseases.

Text Generation

Finally, text generation is the process of composing new, original text in response to a provided prompt.

The basic mechanism revolves around predicting the next word based on the input prompt and the sequence of previously generated words.  As alluded to in the introduction, modern LLMs undergo alignment to prevent toxic, irrelevant, and/or unhelpful text from being generated. This has resulted in improved output.  Text generation can be used for open-domain question answering, in which a general prompt is provided with no corresponding answer in the context (e.g. “What is the purpose of life?”).  Text generation is also used on the downstream end of retrieval-augmented generation pipelines, in which a query first causes the NLP pipeline to filter the relevant documents in a database, extract an answer, and then generate text to present the answer to the user.

In healthcare, potential applications of text generation include helping physicians write clinical notes to ease documentation burden, as well as simplifying routine tasks for health analysts at pharmaceutical companies.  A true challenge is to accomplish these use cases while protecting patient privacy and preventing any PHI leakage in responses to prompts.  At OMNY Health, we strive to accomplish these and related use cases responsibly.

Conclusion

In conclusion, there is more to LLMs than generating text.  Combining text generation functionality with the subtasks mentioned in this article potentiates LLMs to complete powerful tasks that can help improve healthcare.